Background: Glioblastoma (GBM) is a fatal and incurable brain cancer with a dismal prognosis. In 22 order to impact on this disease, we need to understand how infiltrating, non resectable tumour 23 cells resist chemoradiation and facilitate disease recurrence. To this end, we generated or 24 acquired bulk tumour RNA sequencing data from 45 paired primary and locally recurrent GBM 25 tumours (split into original and validation cohorts) from patients that received standard treatment.
BACKGROUND Glioblastoma (GBM) is arguably one of the most challenging cancers to treat and is associated
We performed per-patient GSEA, using our novel gene set, with genes pre-ranked by the that the LE70 JBSgenes correlate with significantly more genes and with significantly more connectivity in recurrent versus primary samples: 1% (29/2603) in the primary GBM network more prevalent post-treatment, or that their co-regulation by JARID2 occurs in response to 171 treatment. To inspect this further we designed an in vitro experiment to investigate the time course 172 of JBSgene dysregulation following treatment.
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Single cell analysis indicates that JARID2 associated gene co-regulation is an adaptive 174 response to therapy treatment when there was a significant deviation in the untreated vs treated spheroid growth curves, and three weeks post-treatment when growth of the treated spheroids appeared to have 180 recovered ( Fig.3 ). Our bespoke GSEA revealed that JBSgenes were significantly enriched 181 amongst the genes altered in treated versus untreated spheroids three-weeks post-treatment 182 (FDR=0.18) but not one week post-treatment (FDR=0.65). Furthermore, the genes that were DE 183 (p<0.05) between treated and untreated cells included significantly more LE50 genes at the three- 
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Complex 2 (PRC2) [12] . PRC2 is a chromatin remodeller that is indispensable for lineage 196 determination during neurogenesis [10] . It is responsible for the trimethylation of lysine 27 on histone conversions between stem-like and differentiated cell types [11] . It is also indirectly implicated by the 207 fact that the prevalence and location of H3K27me3 significantly differs between normal brain and
LE50 JBS All DGC glioma cells, and between GBM cells with different phenotypes [17] . These differences occur most 209 frequently at bivalent promoters: those harbouring both the repressive H3K27me3 and an 210 activating mark (H3K4me3) causing the gene to be silenced but primed for activation upon PRC2 211 disassociation and H3K27 demethylation. Developmental gene promoters are commonly bivalent 212 in embryonic stem cells to enable subsequent rapid activation of specific lineage determination 213 genes once cell fate is resolved, further highlighting PRC2's role in cell-type transitions [18] .
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To determine whether JBSgenes, and specifically the LE50 genes, are implicated in cell expression in different normal and GBM cell types [17, 19] . Normal brain cell types were human 217 neural stem cells (NSCs) and normal human astrocytes (NHAs NSCs in the normal brain) and those which enrich for differentiated glioma cells (DGCs, somewhat analogous to NHAs) [20] . We first quantified promoter status for each different cell types: 
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To determine whether this remodeling associates with gene expression changes we 244 identified genes that are DE (q<0.2) between GSC and DGC using RNAseq data from Patel et 245 al. [19] from matched lines derived from three patient samples. As shown in Fig.5 , we found that 246 significantly more JBSgenes are DE (15% JBSgenes vs 5% of non-JBSgenes; chi-squared, p=0) 247 and that, within the JBSgenes, significantly more LE50 genes are DE (36% of LE50 genes vs 15% 248 of remaining JBSgenes; chi-squared, p=2.5x10 -5 ). We then overlaid the expression and histone 249 mark data and found, as also shown in Fig.5 , that chromatin remodeling involving H3K27me3 is 250 more pronounced at DE JBSgenes (91% of changes at DE JBSgene promoters involve remodeling associated with JARID2 affects the expression of genes that distinguish different cell types in the normal and human brain.
DISCUSSION
and lineage determination, suggesting that GBM cell types defined within neurodevelopmental-like 260 transcriptional hierarchies may be associated with treatment resistance and tumour regrowth in 261 patients. Brain and GBM cell specification results from a combination of the concerted action of 262 transcription factors (TFs) and differential genome accessibility imposed by a variety of chromatin 263 remodeling molecules and complexes. We, therefore, applied an unbiased approach to investigate 264 whether any such DNA-binding factors were repeatedly implicated across patients in the master 265 regulation of genes for which we observe altered expression in recurrent versus primary GBM 266 tumours. We found that genes with Jumonji and AT-Rich Interacting Domain 2 (JARID2) binding 267 site(s) in their promoter (JBSgenes) are consistently and significantly dysregulated in recurrent 268 GBM tumours, in both our original and validation cohorts. JARID2 is indirectly responsible for 269 eliciting the programmes of epigenetic gene silencing required for cell lineage determination during 270 neurodevelopment [9] . It does so by docking Polycomb Repressive Complex 2 (PRC2) to specific 271 genomic loci where it trimethylates H3K27 to repress gene expression [12, 21] . As well as normal 272 brain cell delineation, PRC2 and the H3K27me3 mark have been specifically implicated in cell 273 state transitions in glioblastoma [11, 17, 22] . However, the involvement of JARID2 in this process, and 274 the genes in which expression is altered by this mechanism to dictate GBM cell phenotype have 275 not previously been elucidated. Our results highlight subsets of genes with JARID2 binding sites in 276 their promoters (JBSgenes) that are most commonly dysregulated (LE50 in more than 50% and 277 LE70 in more than 70% of patients) in GBM tumours after treatment. In support of the notion that 278 expression of these genes is regulated by JARID2-assoicated mechanisms in GBM, we have 279 shown that the DNA in their promoters is unmethylated in both primary and recurrent samples and 280 that their promoters are significantly more associated with the H3K27me3 mark than those of other 281 genes in GBM cell lines. The increasing importance of this coordinated regulation by JARID2 in LE70 JBSgenes in recurrent versus primary samples.
specifically resist treatment and are responsible for GBM regrowth [23, 24] . However, a confounding 288 result in relation to this interpretation is the fact that, whilst a specific subset of JBSgenes are 289 universally dysregulated in recurrent versus primary tumours, the direction of dysregulation is 290 inconsistent; the same genes are upregulated in the recurrence in ~70% of patients and down-291 regulated in the remaining 30%. Furthermore, our in vitro work indicates that changes in 292 expression of JBSgenes occurs dynamically following treatment as opposed to resulting from an 293 increased signal from expansion of a fixed transcriptional profile. Our hypothesis is, therefore, that 294 JARID2-associated chromatin remodeling is not a treatment resistance mechanism per se, but a 295 mechanism by which GBM tumours recover from treatment to enable regrowth. In this way, the 296 different directions of gene dysregulation are owing to the need to recapitulate the GBM 297 transcriptional heterogeneity, required for tumour growth in vivo, from whichever cell types 298 survived in that particular patient [13, 25, 26] . This is supported by our findings that the JBSgenes 
Correlation Analysis
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RNAseq data was analysed as previously described except that reads were aligned to human 356 reference genome GRCh38, using the gencode.v27 genome annotation as a guide, using 357 STARv2.4.3a and functional enrichment analysis was done using WebGestalt [28] [29] [30] .
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Gene set enrichment analysis (GSEA)
359
We developed a novel gene set file for use in GSEA using the Gene Transcription Regulation
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Database (GTRD v18.01), which contained the genomic binding locations of 682 human DNA-361 binding factors from 4236 chromatin immunoprecipitation sequencing (ChIPseq) experiments [16] . A 362 gene was assigned to a DNA-binding factor's gene set if its promoter (transcription start site from 363 gencodev27 ±1kbp) contained a binding site for that factor in ≥2 independent ChIPseq 364 experiments. We first performed pre-ranked GSEA, per patient, ordering genes by the magnitude 365 of fold change in expression log 2 (|recurrent FPKM +0.01/primary FPKM+0.01|) in classical mode.
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To indicate directionality of dysregulation we then ranked genes by absolute fold changes ie. using
DNA methylation analysis
The RnBeads package was used to import, quality check and preprocess IDAT files and then perform pairwise differential methylation analysis. The combined and adjusted p-value from untreated spheroids the following day, by extracting and combining 8 spheroids per time point and dissociating them via a PBS wash, Accutase incubation, and further PBS washing (as above)
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